A conceptual framework for the adoption of big data analytics by e-commerce startups: a case-based approach

E-commerce start-ups have ventured into emerging economies and are growing at a significantly faster pace. Big data has acted like a catalyst in their growth story. Big data analytics (BDA) has attracted e-commerce firms to invest in the tools and gain cutting edge over their competitors. The process of adoption of these BDA tools by e-commerce start-ups has been an area of interest as successful adoption would lead to better results. The present study aims to develop an interpretive structural model (ISM) which would act as a framework for efficient implementation of BDA. The study uses hybrid multi criteria decision making processes to develop the framework and test the same using a real-life case study. Systematic review of literature and discussion with experts resulted in exploring 11 enablers of adoption of BDA tools. Primary data collection was done from industry experts to develop an ISM framework and fuzzy MICMAC analysis is used to categorize the enablers of the adoption process. The framework is then tested by using a case study. Thematic clustering is performed to develop a simple ISM framework followed by fuzzy analytical network process (ANP) to discuss the association and ranking of enablers. The results indicate that access to relevant data forms the base of the framework and would act as the strongest enabler in the adoption process while the company rates technical skillset of employees as the most important enabler. It was also found that there is a positive correlation between the ranking of enablers emerging out of ISM and ANP. The framework helps in simplifying the strategies any e-commerce company would follow to adopt BDA in future. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature

The use of mesenchymal stem cells for cartilage repair and regeneration: a systematic review.

BACKGROUND: The management of articular cartilage defects presents many clinical challenges due to its avascular, aneural and alymphatic nature. Bone marrow stimulation techniques, such as microfracture, are the most frequently used method in clinical practice however the resulting mixed fibrocartilage tissue which is inferior to native hyaline cartilage. Other methods have shown promise but are far from perfect. There is an unmet need and growing interest in regenerative medicine and tissue engineering to improve the outcome for patients requiring cartilage repair. Many published reviews on cartilage repair only list human clinical trials, underestimating the wealth of basic sciences and animal studies that are precursors to future research. We therefore set out to perform a systematic review of the literature to assess the translation of stem cell therapy to explore what research had been carried out at each of the stages of translation from bench-top (in vitro), animal (pre-clinical) and human studies (clinical) and assemble an evidence-based cascade for the responsible introduction of stem cell therapy for cartilage defects. This review was conducted in accordance to PRISMA guidelines using CINHAL, MEDLINE, EMBASE, Scopus and Web of Knowledge databases from 1st January 1900 to 30th June 2015. In total, there were 2880 studies identified of which 252 studies were included for analysis (100 articles for in vitro studies, 111 studies for animal studies; and 31 studies for human studies). There was a huge variance in cell source in pre-clinical studies both of terms of animal used, location of harvest (fat, marrow, blood or synovium) and allogeneicity. The use of scaffolds, growth factors, number of cell passages and number of cells used was hugely heterogeneous. SHORT CONCLUSIONS: This review offers a comprehensive assessment of the evidence behind the translation of basic science to the clinical practice of cartilage repair. It has revealed a lack of connectivity between the in vitro, pre-clinical and human data and a patchwork quilt of synergistic evidence. Drivers for progress in this space are largely driven by patient demand, surgeon inquisition and a regulatory framework that is learning at the same pace as new developments take place